Prelude Therapeutics Files 8-K

Ticker: PRLD · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1678660

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Prelude Therapeutics filed an 8-K, likely with updates for investors.

AI Summary

On June 12, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Prelude Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate high risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on June 12, 2024.

What is Prelude Therapeutics Incorporated's state of incorporation?

Prelude Therapeutics Incorporated is incorporated in Delaware.

What is the company's principal executive office address?

The principal executive offices are located at 175 Innovation Boulevard, Wilmington, Delaware 19805.

What is the SEC file number for Prelude Therapeutics Incorporated?

The SEC file number is 001-39527.

Filing Stats: 629 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-06-12 06:55:32

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The Company has prepared a corporate presentation with information about the Company. A copy of the corporate presentation materials to be used by management is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On June 12, 2024, the Company will make available to the public an educational video series on SMARCA degraders via a link on the Investor Relations section of the Company's website, investors.preludetx.com. The slides that will accompany the presentation are attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Website addresses are included as inactive textual references only. The information contained on the website referenced herein is not incorporated into this Current Report on Form 8-K. Important information may be disseminated initially or exclusively via the Company's investor website; investors should consult the site to access this information.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Presentation 99.2 Educational series presentation 104 Cover Page Interactive Data File - the cover page for this Current Report on Form 8-K is formatted in iXBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: June 12, 2024 By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing